W
Wojciech G. Polak
Researcher at Erasmus University Rotterdam
Publications - 150
Citations - 3486
Wojciech G. Polak is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Liver transplantation & Medicine. The author has an hindex of 23, co-authored 104 publications receiving 2118 citations. Previous affiliations of Wojciech G. Polak include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou,Dave Sprengers,Patrick P.C. Boor,Michail Doukas,Hannah M. Schutz,Shanta Mancham,Alexander Pedroza-Gonzalez,Wojciech G. Polak,Jeroen de Jonge,Marcia P. Gaspersz,Haidong Dong,Kris Thielemans,Qiuwei Pan,Jan N.M. IJzermans,Marco J. Bruno,Jaap Kwekkeboom +15 more
TL;DR: The immune checkpoint inhibitory molecules PD-1, TIM3, and LAG3 are up-regulated on TAA-specific T cells isolated from human HCC tissues, compared with T cells from tumor-free liver tissues or blood.
Journal ArticleDOI
First Comparison of Hypothermic Oxygenated PErfusion Versus Static Cold Storage of Human Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis.
Philipp Dutkowski,Wojciech G. Polak,Paolo Muiesan,Andrea Schlegel,Cornelia J. Verhoeven,Irene Scalera,Michelle L. DeOliveira,Philipp Kron,Pierre-Alain Clavien +8 more
TL;DR: No graft failure due to intrahepatic cholangiopathy or nonfunction occurred in HOPE-treated livers, whereas 18% of unperfused DCD livers needed retransplantation.
Journal ArticleDOI
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.
Luca S. Belli,Marina Berenguer,Paolo Cortesi,Mario Strazzabosco,Susanne Rockenschaub,Silvia Martini,C. Morelli,Francesca Donato,Riccardo Volpes,Georges Philippe Pageaux,Audrey Coilly,Stefano Fagiuoli,Giuliana Amaddeo,Giovanni Perricone,Carmen Vinaixa,Gabriela A. Berlakovich,Rita Facchetti,Wojciech G. Polak,Paolo Muiesan,Christophe Duvoux +19 more
TL;DR: This study shows for the first time that the DAAs may lead to a remarkable clinical improvement allowing the delisting of one patient out of 5 in 60weeks, respectively.
Journal ArticleDOI
A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort.
Jeroen L.A. van Vugt,Louise J. M. Alferink,Stefan Buettner,Marcia P. Gaspersz,D. Bot,Sarwa Darwish Murad,Shirin Feshtali,Peter M. A. van Ooijen,Wojciech G. Polak,Robert J. Porte,Bart van Hoek,Aad P. van den Berg,Herold J. Metselaar,Jan N. M. IJzermans +13 more
TL;DR: Low skeletal muscle mass was associated with mortality on the waiting list, particularly in patients who were listed with low priority based on a low MELD score, however, adding these measurements to the currently used system for donor and organ allocation showed no added value.
Journal ArticleDOI
Defining Benchmarks in Liver Transplantation: A Multicenter Outcome Analysis Determining Best Achievable Results.
Xavier Muller,F. Marcon,Gonzalo Sapisochin,Max Marquez,Federica Dondero,Michel Rayar,Majella B. Doyle,Lauren Callans,Jun Li,Greg Nowak,Marc Antoine Allard,Ina Jochmans,Kyle Jacskon,Magali Chahdi Beltrame,Marjolein van Reeven,Samuele Iesari,Alessandro Cucchetti,Hemant Sharma,Hemant Sharma,Roxane D Staiger,Dimitri A. Raptis,Henrik Petrowsky,Michelle L. de Oliveira,Roberto Hernandez-Alejandro,Roberto Hernandez-Alejandro,Antonio Daniele Pinna,Jan Lerut,Wojciech G. Polak,Eduardo de Santibañes,Martin de Santibañes,Andrew M. Cameron,Jacques Pirenne,Daniel Cherqui,René Adam,Bo Göran Ericzon,Bjoern Nashan,Kim M. Olthoff,Avi Shaked,William C. Chapman,Karim Boudjema,Olivier Soubrane,Catherine Paugam-Burtz,Paul D. Greig,David R. Grant,Amanda Carvalheiro,Paolo Muiesan,Philipp Dutkowski,Milo A. Puhan,Pierre-Alain Clavien +48 more
TL;DR: Despite excellent 1- year survival, morbidity in benchmark cases remains high with half of patients developing severe complications during 1-year follow-up, and benchmark cutoffs targeting morbidity parameters offer a valid tool to assess higher risk groups.